Project Details
Description
SBIR submission Collaborations Phannaceuticals "Characterization and Development of a Nipah virus inhibitor'' (January 2023) Specific aims and tasks:
- Evaluate the antiviral activity of pyronaridine and derivates against Nipah virus (NiV) in vitro. Oetennine ECso, EC9o., CCso, and SI values.
- Evaluate the antiviral efficacy of pyronaridine or derivatives in the Syrian Golden Hamster model for NiV. These experiments include a dose-finding study, a time to failure study, as well as a natural history of disease study.
| Status | Active |
|---|---|
| Effective start/end date | 9/15/23 → 8/31/25 |
Funding
- Collaborations Pharmaceuticals, Inc ( Award #1R43AI17435001A1): $97,381.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.